Transarterial Chemoembolization (TACE)
Treatment for Liver Cancer Due To Hepatitis C
Effectiveness
70%
Safety Score
60%
Clinical Trials
100
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Time to Effect
1-2 months
Treatment Duration
Multiple sessions (1-3+ per year), ongoing surveillance
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$7,500
Side Effect Mgmt:$2,000
Total Annual:$9,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$15,833
Comparison vs Best Supportive Care
Cost Difference
+$20,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Transarterial Chemoembolization (TACE) Outcomes
for Liver Cancer Due To Hepatitis C
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+60%
Common Side Effects
Post-embolization syndrome (fever, pain, nausea)
+70%
Liver dysfunction
+10%
Biloma/abscess
+2%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov